ANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorZamoner, Welder-
Autor(es): dc.creatorScardini, Julia Baldon-
Autor(es): dc.creatorDe Dio, Bruna Jordana-
Autor(es): dc.creatorMarques, Amanda de Melo-
Autor(es): dc.creatorSilva, Vanessa dos Santos-
Autor(es): dc.creatorGarcia, Aline Lutz-
Autor(es): dc.creatordos Santos, Daniela Cristina-
Autor(es): dc.creatorViero, Rosa Marlene-
Data de aceite: dc.date.accessioned2025-08-21T16:24:36Z-
Data de disponibilização: dc.date.available2025-08-21T16:24:36Z-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2023-07-29-
Data de envio: dc.date.issued2022-10-06-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.3389/fmed.2022.1003332-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/247761-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/247761-
Descrição: dc.descriptionThis article presents a case of rapidly progressive glomerulonephritis following the Oxford-AstraZeneca COVID-19 vaccine in a female patient 58 years old. After 5 days, she presented fatigue, paleness, arthralgia on hands, knees, ankles, foamy urine, and elevated blood pressure. Exams showed serum creatinine of 2.2 mg/dL (baseline creatinine of 1.0 mg/dL). Urinalysis revealed hematuria, and her 24-h urinary protein excretion was 4.4 g. Additional exams showed hypercholesterolemia, severe anemia, and normal serum albumin. Testing of antineutrophil cytoplasmic antibodies anti-myeloperoxidase was positive at a titer of 1/80. Serum and urine protein electrophoresis and other exams showed no alterations. She was started on steroid pulse therapy after worsening kidney function, reaching serum creatinine of 3.3 mg/dL. A kidney biopsy revealed crescentic glomerulonephritis with glomerular sclerosis, fibrous crescents, interstitial fibrosis, and tubular atrophy. Induction therapy was given with intravenous cyclophosphamide 0.5 g/m2 for 6-monthly pulses, followed by maintenance therapy with oral azathioprine at 2 mg/kg and prednisone tapering. The patient did not develop any complications during the induction therapy, and is currently on maintenance therapy with a serum creatinine of 1.87 mg/dL.-
Descrição: dc.descriptionDepartment of Internal Medicine Discipline of Nephrology Botucatu School of Medicine University São Paulo State—UNESP-
Descrição: dc.descriptionDepartment of Pathology Botucatu School of Medicine University São Paulo State—UNESP, São Paulo-
Descrição: dc.descriptionDepartment of Internal Medicine Discipline of Nephrology Botucatu School of Medicine University São Paulo State—UNESP-
Descrição: dc.descriptionDepartment of Pathology Botucatu School of Medicine University São Paulo State—UNESP, São Paulo-
Idioma: dc.languageen-
Relação: dc.relationFrontiers in Medicine-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectacute kidney injury-
Palavras-chave: dc.subjectAstraZeneca-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectOxford-
Palavras-chave: dc.subjectvaccine-
Título: dc.titleANCA-associated vasculitis following Oxford-AstraZeneca COVID-19 vaccine in Brazil: Is there a causal relationship? A case report-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.